InteloMed, Inc. Announces Engagement of Investment Banking Firm Healthios Capital Markets, LLC as Exclusive Financial Advisor for Regulation D Private Placement
PITTSBURGH, PA–(Marketwired – Sep 6, 2016) – InteloMed, Inc. (“InteloMed”), an emerging leader and developer of advanced non-invasive systems for patient monitoring and informatics, announced today that it has retained Healthios Capital Markets, LLC (“Healthios”), a premier investment bank focused on the global healthcare industry, as its exclusive financial advisor in connection with a Regulation …
“InteloMed is excited to partner with Healthios, an investment bank with unique expertise in the field of healthcare funding and a history of successful transactions,” said InteloMed CEO Jill Schiaparelli. “We look forward to working with Healthios to help us grow InteloMed and empower clinical decision-making with advanced non-invasive monitoring and informatics solutions.”
About InteloMed and the CVInsight® Patient Monitoring & Informatics System
InteloMed is redefining the standard of care in patient monitoring and informatics through its CVInsight® Patient Monitoring & Informatics System, a non-invasive advanced monitoring system. It empowers clinicians with real-time, dynamic, and actionable information about a patient’s cardiovascular stress level. Based on patented and proprietary algorithms, the system provides clinician-set alerts in response to changes in the patient’s tolerance to illness, treatment and trauma, allowing them to provide immediate and appropriate interventions. The CVInsight® System can be used across a variety of healthcare settings and is FDA-cleared and CE-marked. The system has launched commercially in the US with initial focus in the dialysis market.
InteloMed is headquartered in Wexford, PA. For more information, visit us at www.InteloMed.com.
About Healthios Capital Markets, LLC
Healthios Capital Markets, LLC, founded in 2005 and based in Northbrook, IL, offers strategic advisory and investment banking services to emerging growth healthcare companies.
** News, Media, PR and Content distribution provided by 1-800-PublicRelations, Inc.
Contact Information
InteloMed
Michael Dignazio
CFO
MDignazio@InteloMed.com
412.536.7654
Healthios
Christoph Brandenberger
Managing Director
CBrandenberger@Healthios.com
847.849.1739
(Investors with accredited status only)
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1876.60 | -17.33 | |
Silver | 22.50 | -0.51 | |
Copper | 4.29 | 0.00 | |
Palladium | 2186.50 | -69.50 | |
Platinum | 984.50 | -13.50 | |
Oil | 108.65 | +0.39 | |
Heating Oil | 4.06 | +0.02 | |
Natural Gas | 8.86 | +0.08 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.